What kind of drug does Tucatinib belong to?

Tucatinib (Tucatinib) is an anticancer drug. Specifically, it is an oral small molecule tyrosine kinase inhibitor (Tyrosine Kinase Inhibitor, TKI), specifically targets human epidermal growth factor receptor 2 (HER2). HER2 is a receptor tyrosine kinase that is often overexpressed in certain cancer types, especially breast and gastric cancers. HER2Positive breast cancer refers to breast cancer with a large number of HER2 receptors on the surface of cancer cells, accounting for about 15-20% of all breast cancer cases.

As a HER2 specific TKI, tucatinib prevents the activation of HER2 signaling pathway by highly selectively inhibiting the tyrosine kinase activity of HER2. This property gives tucatinib (tucatinib) a unique advantage in the treatment of HER2-positive breast cancer. Unlike other TKIs, Tucatinib is more selective for HER2 and reduces the inhibition of HER1 (EGFR), thereby reducing common side effects such as rash and diarrhea.

The mechanism of action of Tucatinib is mainly to inhibit the proliferation and survival of cancer cells by blocking the HER2 signaling pathway. HER2The receptor activates its tyrosine kinase activity through dimerization on the surface of cancer cells, initiating multiple signaling pathways for cell proliferation and survival, such as the PI3K/AKT and MAPK pathways. Tucatinib blocks the activation of these signaling pathways by binding to the tyrosine kinase domain of HER2 , thereby inhibiting the growth and spread of cancer cells.

In addition, tucatinib is often given in combination with other antiHER2 drugs, such as trastuzumab and capecitabine. This combined treatment strategy significantly improves the treatment effect and prolongs the progression-free survival and overall survival of patients. Especially in the treatment of brain metastases from HER2positive breast cancer, tucatinib (tucatinib) has shown good efficacy because it can penetrate the blood-brain barrier and directly act on HER2positive cancer cells in the brain.